Clofilium

Steinberg, Mitchell I.; Lindstrom, Terry D.; Fasola, Alfred F.

doi:10.1111/j.1527-3466.1984.tb00460.x

Cited by 3 publications

(2 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ampicillin caused marked QT prolongation, AV block, and proarrhythmia in a neonate [68] and in another patient, lasting for several days [146]. In contrast, clofilium prolongs the QT interval markedly, but has a negligible proarrhythmic effect [219].…”

Section: Characteristics Of Proarrhythmia After Drug-lnduced Qt Prolomentioning

confidence: 98%

QT-Interval prolonging drugs: Mechanisms and clinical relevance of their arrhythmogenic hazards

Zehender

Hohnloser

Just

1991

Cardiovasc Drug Ther

View full text Add to dashboard Cite

The antiarrhythmic principle of drug-induced QT-interval prolongation is well known. However, with the widespread use of the presently known and new Class III antiarrhythmic agents under investigation, and the growing number of agents not primarily designed as antiarrhythmic drugs that potentially cause QT prolongation, we have also become aware of the proarrhythmic hazards associated with many of these agents. The proarrhythmic risk differs markedly from one agent to another and interferes with many individual clinical variables (e.g., hypokalemia, sinus bradycardia). This paper summarizes the present data on the proarrhythmic risk of drug-induced QT prolongation, including the value and problems of the rate-corrected QT interval, the mechanisms involved in the genesis of proarrhythmia, and the clinical cofactors that facilitate the occurrence of proarrhythmic events. In addition, an extensive database provides information on the known proarrhythmic risk of all currently used QT-prolonging agents.

show abstract

Section: Characteristics Of Proarrhythmia After Drug-lnduced Qt Prolomentioning

confidence: 98%

QT-Interval prolonging drugs: Mechanisms and clinical relevance of their arrhythmogenic hazards

Zehender

Hohnloser

Just

1991

Cardiovasc Drug Ther

View full text Add to dashboard Cite

show abstract

“…For control animals, ESo increased by a mean 34+78%, 60±83%, and 69±122% compared with baseline (day 7) on days 14, 21, and 28, respectively. In contrast, Eso in clofilium-treated dogs decreased by 39±62%, 24 ±33%, and 32±15% on days 14, 21, and 28, respectively. Mean current requirements (I1o) remained relatively stable compared with baseline in control animals (-7±39%o, +25±36%, +40±75% on days 14, 21, and 28, respectively).…”

mentioning

confidence: 80%

Oral clofilium produces sustained lowering of defibrillation energy requirements in a canine model.

et al. 1991

View full text Add to dashboard Cite

The effect of long-term oral administration of antiarrhythmic drugs on defibrillation energy requirements is not well understood. We examined the effect of clofilium, a drug that prolongs cardiac action potential duration without slowing cardiac conduction, on defibrillation energy requirements and ventricular effective refractory periods in a canine model during a 3-week period. Epicardial patch electrodes were implanted in 12 dogs, and baseline testing was conducted under fentanyl anesthesia on day 7. An oral clofilium (100 mg/day) regimen was started on day 8. Six clofilium-treated and six control dogs underwent repeated testing on days 14, 21, and 28 after surgery. Truncated trapezoidal shocks were given repeatedly at various stored energies in random order; delivered current and impedance were measured; and delivered energy was calculated. The energy and current for 50% success in defibrillation (E50 and I50, respectively) were determined. For control animals, E50 increased by a mean 34 +/- 78%, 60 +/- 83%, and 69 +/- 122% compared with baseline (day 7) on days 14, 21, and 28, respectively. In contrast, E50 in clofilium-treated dogs decreased by 39 +/- 62%, 24 +/- 33%, and 32 +/- 15% on days 14, 21, and 28, respectively. Mean current requirements (I50) remained relatively stable compared with baseline in control animals (-7 +/- 39%, +25 +/- 36%, +40 +/- 75% on days 14, 21, and 28, respectively). After clofilium administration I50 decreased by 36 +/- 22%, 32 +/- 17%, and 33 +/- 17% on days 14, 21, and 28, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract